Hervé Avet-Loiseau
French Institute of Health and Medical Research
501 Papers
3.2K Citations
Hervé Avet-Loiseau is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 93, co-authored 454 publications. Previous affiliations of Hervé Avet-Loiseau include University of California, San Francisco & Centre Hospitalier Universitaire de Toulouse.
Chat about Author
Papers
Nuclease Activity Is Associated with Genomic Instability As Well As Survival in Myeloma; Underlying Mechanisms and Significance
Masood A. Shammas,Masood A. Shammas,Leutz Buon,Jianhong Lin,Mehmet Kemal Samur,Jaymin M. Patel,Ankit V Vahia,Puru Nanjappa,Subodh Kumar,Subodh Kumar,Ahsun Bajwa,Humza Ahmad,David A. Alagpulinsa,David A. Alagpulinsa,Giovanni Parmigiani,Florence Magrangeas,Stephane Minvielle,Hervé Avet-Loiseau,Nikhil C. Munshi,Nikhil C. Munshi +19 more
TL;DR: Avet-Loiseau et al. as mentioned in this paper developed a nuclease gene signature correlating with both the genomic instability and survival in multiple myeloma patients, and found correlation between nucleases activity and genomic instability with impact on survival.
2
Redefining Mutational Profiling Using RNA-Seq: Insight into the Functional Mutational Landscape of Multiple Myeloma
David Mosen-Ansorena,Niccolo Bolli,Niccolo Bolli,Mehmet Kemal Samur,Florence Magrangeas,Stephane Minvielle,Kenneth C. Anderson,Peter J. Campbell,Hervé Avet-Loiseau,Giovanni Parmigiani,Nikhil C. Munshi +10 more
TL;DR: The first computational analysis to identify mutational driver genes using RNA-seq data is reported, providing additional insight into the mutational landscape of MM.
2
S874 efficacy of daratumumab + bortezomib/thalidomide/dexamethasone (d-vtd) in transplant-eligible newly diagnosed multiple myeloma based on minimal residual disease status: analysis of cassiopeia
Hervé Avet-Loiseau,Philippe Moreau,V.H.J. van der Velden,Michel Attal,Cyrille Hulin,Bertrand Arnulf,Jill Corre,Laurent Garderet,Lionel Karlin,Jérôme Lambert,Margaret Macro,Aurore Perrot,Pieter Sonneveld,Mark-David Levin,Saskia K. Klein,Christopher Chiu,L. Pe,Veronique Vanquickelberghe,C. de Boer,Tobias Kampfenkel,Jessica Vermeulen,Soraya Wuilleme,M C Béné +22 more
- 01 Jun 2019
2
Bone Marrow Microenvironment Affects The Pathogenesis Of Multiple Myeloma Through Downregulation Of Alternative Splicing Factor Fox2 In Myeloma Cells
Chaolin Zhang,Yiguo Hu,Maria Gkotzamanidou,Parantu K. Shah,Weisong Shan,Guang Yang,Samir B. Amin,Yu-Tzu Tai,Yi Li,Adam S. Sperling,Naim U. Rashid,Florence Magrangeas,Stephane Minvielle,Hervé Avet-Loiseau,Kenneth C. Anderson,Cheng Li,Nikhil C. Munshi +16 more
TL;DR: The results identify Fox2 as a biologically important splicing factor with essential function and potential clinical implications in multiple myeloma, as one of the most important genes predicting clinical outcome in these patients.
2
Use of high-density SNP-array analysis to identify novel chromosomal abnormalities that predict survival in multiple myeloma
Hervé Avet-Loiseau,Nikhil C. Munshi,Cheng Li,Florence Magrangeas,Wilfried Gouraud,Catherine Charbonnel,KC Anderson,P. Moreau,Loïc Campion,Stephane Minvielle,Intergroupe Francophone du Myelome +10 more
TL;DR: The spectrum of unbalanced chromosomal abnormalities in myeloma is defined using the Affymetrix 500K SNP arrays to study a cohort of 192 patients ≤ 65 years of age, homogeneously treated with high dose chemotherapy in the IFM 99 trials.
2